How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

  title={How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins},
  author={F.C.J. Starrenburg and J. P. A. M. Bogers},
  journal={European Psychiatry},
  pages={164 - 170}

Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor

The potential candidature of the acetylcholine (ACh) muscarinic M3 receptor (M3R) as a prime mechanistic and possible therapeutic target of interest in SGA-induced insulin dysregulation is explored.

Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

The metabolic and cardiovascular risks of various antipsychotic medications in adults and children are outlined, the disparities in health care are defined, and recommendations for screening and monitoring of patients taking these agents are made.

The Role of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-Genetic Factors

Preclinical, clinical, and genetic data are reviewed in order to infer the potential role played by leptin in antipsychotic-induced weight gain considering two main hypotheses: (1) leptin is an epiphenomenon of weight gain; (2)ptin is a consequence of antipsychotics-induced “leptin-resistance status,” causing weight gain.

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia

Patients on risperidone and clozapine therapy may be at greater risk of developing metabolic syndrome than patients treated with aripiprazole.



Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors.

It is conceivable that olanzapine interferes either directly or indirectly with the insulin signaling pathway, as new assays for some of these adipose tissue–derived insulin resistance–inducing factors have recently become available.

H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs

It is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H1-histamine receptors, which are known to induce weight gain with chronic use.

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

A review examines the potential contribution of different receptors to metabolic side effects associated with atypical antipsychotic treatment for all seven agents currently marketed in the United States and another agent in clinical development at the time of this publication.

Hyperglycemia associated with the use of atypical antipsychotics.

These studies indicate that hyperglycemia is not dose dependent, is reversible on cessation of treatment with clozapine or olanzapine, and reappears on reintroduction of these therapies.

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Both nonobese clozapine- and olanzapine's and risperidone's treatment with atypical antipsychotic agents displayed significant insulin resistance and impairment of glucose effectiveness compared with ris peridone-treated subjects.

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

Olanzapine treatment was associated with weight gain and elevated levels of insulin, leptin, and blood lipids as well as insulin resistance, with 3 patients diagnosed to have diabetes mellitus.

Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients.

The results reported in this study suggest the effect of previous antipsychotic treatment on glucose metabolism parameters and weight-related hormones such as leptin, while ruling out a preexisting impairment of glucose metabolism in never-medicated first-episode schizophrenic patients.

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

Although in its infancy, psychiatric pharmacogenetics will in the future aid clinical practice in the prediction of response and side effects, such as antipsychotic-induced weight gain, and minimize the current "trial and error" approach to prescribing.

Atypical antipsychotics and glucose homeostasis.

Atypical antipsychotics have been shown to contribute to weight gain, which may well reflect increased body fat deposition, and failure of adequate pancreatic beta-cell compensation for insulin resistance plays a central role in the pathogenesis of diabetes associated with this class of drugs.